Toxic epidermal necrosishttps://en.wikipedia.org/wiki/Toxic_epidermal_necrolysis
Toxic epidermal necrosis o se ituaiga fa'alavelave tuga o le pa'u. O fa'ailoga muamua e aofia ai le fiva ma fa'ailoga pei o le fulū. I ni nai aso mulimuli ane, e amata ona pa'u le pa'u ma fai ai ni vaega ma'i tiga. E taua tele mucous membranes, e pei o le gutu, e masani ona aʻafia. O fa'alavelave e aofia ai le mamaina o le vai, sepsis, niuponia, ma le tele o totoga e le manuia.

Ole mafua'aga sili ona masani o vaila'au fa'apitoa e pei o le lamotrigine, carbamazepine, allopurinol, sulfonamide antibiotic, ma nevirapine. O a'afiaga e aofia ai le HIV ma le systemic lupus erythematosus. Togafitiga e masani lava ona faia i le falema'i e pei o le vaega mu po'o le potu mo gasegase tigaina.

Togafiti
O se fa'ama'i tuga lea, afai e a'afia lou laugutu po'o lou gutu po'o le pa'u, va'ai i lau foma'i i se taimi vave.
O vaila'au masalo e tatau ona fa'agata (e.g., antibiotics, non‑steroidal anti‑inflammatory drugs).

☆ AI Dermatology — Free Service
I le 2022 Stiftung Warentest i'uga mai Siamani, o le fa'amalieina o tagata fa'atau i ModelDerm sa na'o sina maualalo ifo nai lo fa'atalanoaga telemedicine totogi.
  • O le ā le uiga o le Toxic epidermal necrosis?
  • TENS – aso 10.
  • Necrolysis epidermalis toxica (Toxic epidermal necrolysis)
  • E mafai ona vave fa‘asolo le ma‘i i le amataga ma aafia ai le tino atoa i totonu o ni nai aso.
References Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management 34577817 
NIH
Stevens-Johnson Syndrome (SJS) ma Toxic Epidermal Necrolysis (TEN) o ni tulaga e seasea ona maua le pa'u o le necrosis tele ma le maligi. I le tulaga o togafitiga, o le cyclosporine e sili ona aoga mo le SJS, ae o le tuʻufaʻatasiga o le immunoglobulin intravenous (IVIg) ma corticosteroids e sili ona aoga mo mataupu o le SJS ma le TEN.
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare diseases that are characterized by widespread epidermal necrosis and sloughing of skin. Regarding treatment, cyclosporine is the most effective therapy for the treatment of SJS, and a combination of intravenous immunoglobulin (IVIg) and corticosteroids is most effective for SJS/TEN overlap and TEN.
 Toxic Epidermal Necrolysis: A Review of Past and Present Therapeutic Approaches 36469487
Toxic epidermal necrolysis (TEN) o se fa'alavelave tuga o le pa'u e mafua mai i vaila'au fa'apitoa ma fa'agaoioiga o le puipuiga o le tino, e i'u ai i le fa'ateteleina o le pa'u pito i fafo (epidermis), e a'afia ai le sili atu i le 30% o le tino. O le TEN e sili atu i le 20% le aofa'i o tagata maliliu, e masani lava ona o ma'i pipisi ma faigata ona manava. O le taofi o vaila'au e mafua ai le fa'alavelave, tuʻuina atu o le tausiga lagolago, ma le faʻaaogaina o togafitiga faa'opoopo e mafai ona fa'aleleia le taunuuga. Su'esu'ega talu ai nei ua fa'aalia ai o vaila'au e pei o le cyclosporine, tumor necrosis factor alpha inhibitors, ma le tu'ufa'atasia o le intravenous immune globulin ma corticosteroids e mafai ona fesoasoani, fa'avae i luga o fa'ata'ita'iga fa'atonutonu ma su'esu'ega o le tele o su'esu'ega.
Toxic epidermal necrolysis (TEN) is a serious skin reaction caused by certain medications and immune system activity, resulting in large-scale detachment of the outer skin layer (epidermis), affecting more than 30% of the body's surface. TEN has a mortality rate of over 20%, often due to infections and breathing difficulties. Stopping the medication causing the reaction, providing supportive care, and using additional treatments can improve the outcome. Recent studies have shown that drugs like cyclosporine, tumor necrosis factor alpha inhibitors, and a combination of intravenous immune globulin and corticosteroids can be helpful, based on randomized controlled trials and analyses of multiple studies.
 Toxic Epidermal Necrolysis and Steven–Johnson Syndrome: A Comprehensive Review 32520664 
NIH
Recent Advances: There is improved understanding of pain and morbidity with regard to the type and frequency of dressing changes. More modern dressings, such as nanocrystalline, are currently favored as they may be kept in situ for longer periods. The most recent evidence on systemic agents, such as corticosteroids and cyclosporine, and novel treatments, are also discussed.